MYC and diffuse large B-cell lymphoma: We conducted a single‐centre phase 1/2 trial of VVIP in patients with R/R PTCL, MYC‐rearranged DLBCL/HGBCL and non‐germinal centre B‐cell (GCB) DLBCL.